Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity First-in-class, oral PKM2 modulator, SYX-5219, has the ...

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

The global atopic dermatitis market size was valued at USD 6.62 billion in 2025 and is predicted to hit around USD 12.97 billion by 2034, rising at a 7.75% CAGR, a study published by Towards ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...